Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $69.00

Greenwich LifeSciences (NASDAQ:GLSI) had its price target raised by HC Wainwright from $50.00 to $69.00 in a report issued on Tuesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.29) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.29) EPS and FY2027 earnings at ($1.17) EPS.

A number of other research firms have also recently issued reports on GLSI. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Price Performance

NASDAQ GLSI opened at $13.19 on Tuesday. The business has a fifty day moving average price of $22.43 and a two-hundred day moving average price of $24.45. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10. The stock has a market capitalization of $193.63 million, a PE ratio of -8.40 and a beta of 1.40.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Sei Investments Co. bought a new stake in shares of Greenwich LifeSciences in the 1st quarter valued at about $627,000. Bank of New York Mellon Corp raised its position in shares of Greenwich LifeSciences by 235.5% during the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after acquiring an additional 32,657 shares during the last quarter. Strs Ohio raised its position in shares of Greenwich LifeSciences by 140.4% during the first quarter. Strs Ohio now owns 13,700 shares of the company’s stock worth $329,000 after acquiring an additional 8,000 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Greenwich LifeSciences during the fourth quarter worth about $605,000. Finally, XTX Topco Ltd acquired a new position in shares of Greenwich LifeSciences in the fourth quarter worth approximately $217,000. 4.16% of the stock is owned by institutional investors.

Trending Headlines about Greenwich LifeSciences

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: UK regulators approved expansion of the company’s Phase III FLAMINGO-01 breast cancer trial into the United Kingdom, potentially adding 5-10 new sites and broadening patient enrollment. Greenwich LifeSciences said the move was supported by patient interest and its collaboration with The Royal Marsden, which could improve visibility and trial momentum for GLSI-100. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and $69 price target on GLSI while slightly lifting its Q2 2026 EPS estimate and reiterating longer-term forecasts. Even though the company is still expected to post losses, the higher estimates and bullish rating suggest analysts remain constructive on the stock’s clinical upside. Article Title
• Neutral Sentiment: HC Wainwright also set out FY2026 and FY2027 EPS estimates, both still negative, indicating Greenwich LifeSciences remains a pre-revenue clinical-stage biotech with ongoing losses. That keeps valuation tied heavily to trial progress rather than near-term earnings. Article Title
• Neutral Sentiment: Investor materials highlighted preliminary FLAMINGO-01 data showing a roughly 70-80% reduction in recurrence rates in one arm of the study, but the company emphasized the results are not final and remain subject to clinical uncertainty. The data are encouraging, but still early enough that investors are likely to wait for more definitive readouts. Article Title

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.